Innate Pharma's Key Phase 3 Trial Hinges on Financing; FY25 Results Detail Q3 2026 Cash Runway
summarizeSummary
Innate Pharma reported its full-year 2025 financial results, highlighting a cash position of EUR44.8 million as of December 31, 2025, providing a cash runway until the end of Q3 2026. A significant update is the planned initiation of the confirmatory Phase 3 TELLOMAK-3 trial for lacutamab in H2 2026, which is explicitly subject to securing non-dilutive financing options. This contingency introduces a material risk factor for the company's lead asset. Additionally, the company provided positive updates on its IPH4502 Nectin-4 ADC, showing preliminary anti-tumor activity, and confirmed the Monalizumab PACIFIC-9 Phase 3 trial (partnered with AstraZeneca) is advancing towards a H2 2026 data readout. Interim results for IPH5201 (also partnered with AstraZeneca) have been selected for an oral presentation at AACR 2026, providing positive visibility. Traders will focus on the company's ability to secure the necessary financing for the lacutamab Phase 3 trial and the upcoming data readouts.
At the time of this announcement, IPHA was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.8M. The 52-week trading range was $1.17 to $2.63. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.